Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Auckland. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
RO7565020 is being developed for the treatment of Chronic Hepatitis B (CHB), whereby chronic infection with Hepatitis B virus (HBV) can lead to liver damage and potentially liver cancer. RO7565020 is designed to target and reduce the levels of Hepatitis B surface antigen (HBsAg) in the hopes of providing a functional cure for CHB.
The purpose of part 1a of this study is to:
● Evaluate how safe and well tolerated single doses of RO7565020 is, in healthy participants
● Measure levels of RO7565020 in the blood over time, following a single dose, in healthy participants
● Measure the body’s response to a single dose of RO7565020
● Assess the body’s immune response to RO7565020
Study Candidates
- Males and females (on contraception)
- Aged 18 – 65 years
- BMI 18 – 32 kg/m2
- Non-smokers
- Not taking any medications
What is Involved?
Inpatient Stay: 4 nights
Follow-Up: 9 visits
Reimbursement: $8,000 (less tax)